Cutera (NASDAQ:CUTR) Now Covered by StockNews.com

Research analysts at StockNews.com started coverage on shares of Cutera (NASDAQ:CUTR) in a report issued on Sunday. The brokerage set a “sell” rating on the medical device company’s stock.

Cutera Stock Performance

CUTR opened at $0.48 on Friday. The company’s 50-day simple moving average is $0.41 and its two-hundred day simple moving average is $0.80. Cutera has a 52-week low of $0.28 and a 52-week high of $4.97. The stock has a market capitalization of $9.77 million, a P/E ratio of -0.07 and a beta of 1.31.

Hedge Funds Weigh In On Cutera

Several hedge funds and other institutional investors have recently modified their holdings of the company. Squarepoint Ops LLC lifted its holdings in Cutera by 164.5% in the second quarter. Squarepoint Ops LLC now owns 113,964 shares of the medical device company’s stock valued at $172,000 after acquiring an additional 70,870 shares during the period. Bank of Montreal Can increased its position in shares of Cutera by 14.2% during the 2nd quarter. Bank of Montreal Can now owns 282,704 shares of the medical device company’s stock valued at $455,000 after purchasing an additional 35,248 shares during the last quarter. Finally, Ground Swell Capital LLC bought a new position in shares of Cutera in the 2nd quarter worth approximately $37,000. 90.70% of the stock is owned by institutional investors.

About Cutera

Cutera, Inc provides aesthetic and dermatology solutions for medical practitioners worldwide. It develops, manufactures, and markets energy-based product platforms for medical practitioners; and distributes third-party manufactured skincare products. The company provides AviClear for the treatment of mild, moderate, and severe inflammatory acne vulgaris; Secret PRO, a device that utilizes fractional CO2 for skin resurfacing and radio frequency (RF) microneedling for skin revitalization; truFlex, a bio-electrical muscle stimulation device designs to strengthen, firm and tone the abdomen, buttocks, and thighs; and excel V/V+, a vascular and benign pigmented lesion treatment platform.